Improving quality of life through the routine use of the patient concerns inventory for head and neck cancer patients: a cluster preference randomized controlled trial

Simon N. Rogers1,2,10*, Derek Lowe1,2, Cher Lowies3, Seow Tien Yeo4, Christine Allmark5, Dominic Mcavery1, Gerald M. Humphris6, Robert Flavel7, Cherith Semple8, Steven J. Thomas9 and Anastasios Kanatas5

Abstract

Background: The consequences of treatment for Head and Neck cancer (HNC) patients has profound detrimental impacts such as impaired QOL, emotional distress, delayed recovery and frequent use of healthcare. The aim of this trial is to determine if the routine use of the Patients Concerns Inventory (PCI) package in review clinics during the first year following treatment can improve overall quality of life, reduce the social-emotional impact of cancer and reduce levels of distress. Furthermore, we aim to describe the economic costs and benefits of using the PCI.

Methods: This will be a cluster preference randomised control trial with consultants either 'using' or 'not using' the PCI package at clinic. It will involve two centres Leeds and Liverpool. 416 eligible patients from at least 10 consultant clusters are required to show a clinically meaningful difference in the primary outcome. The primary outcome is the percentage of participants with less than good overall quality of life at the final one-year clinic as measured by the University of Washington QOL questionnaire version 4 (UWQOLv4). Secondary outcomes at one-year are the mean social-emotional subscale (UWQOLv4) score, Distress Thermometer (DT) score ≥ 4, and key health economic measures (QALY-EQ-SD-5 L; CSRI).

Discussion: This trial will provide knowledge on the effectiveness of a consultation intervention package based around the PCI used at routine follow-up clinics following treatment of head and neck cancer with curative intent. If this intervention is (cost) effective for patients, the next step will be to promote wider use of this approach as standard care in clinical practice.

Trial registration: 32,382. Clinical Trials Identifier, NCT03086629. Protocol: Version 3.0, 1st July 2017.

Keywords: Head and neck Cancer, Patient concerns inventory, Quality of life, Patient reported outcomes, Intervention
Background

The incidence of Head and neck cancer (HNC) is increasing, the three main sites being oral cavity (mouth), oropharynx (throat) and larynx (voice box) with about 11,000 new cancers in the UK each year [http://www.cancerresearchuk.org/about-cancer/mouth-cancer]. Treatments such as surgery and chemo-radiotherapy have a detrimental effect on basic day management issues will be addressed with each unit and repeating opportunities to raise issues they feel are important - notably fears of recurrence, anxiety and depression [15, 16]. Hence the PCI could help clinician communication with patients in these important areas and consequently impact on how consultations are constructed.

The PCI provides a process by which the patient has repeated opportunities to raise issues they feel are important and that they want to discuss. It can be argued that the routine repeated use of the PCI in follow-up clinics will benefit patients wanting support to speak more openly about problems or concerns e.g. psychosocial causes of symptoms; need for psychosocial help; to seek explanation and reassurance for more physical explanations about their cancer and about the side-effects of treatment. It is postulated that this will have a positive impact on quality of life and emotional distress and be demonstrable by one year following HNC treatment [17]. Thus far, the majority of evidence related to the PCI-HN has been derived from one clinic setting. By conducting a randomised controlled trial (RCT) across multiple consultants, it will be possible to rigorously evaluate if the repeated inclusion of the PCI-HN in routine post-treatment consultations does make a significant and clinically meaningfully difference in patient reported quality of life and distress.

Methods/design

This is a preference cluster randomised control trial with consultants either ‘using or ‘not using’ the PCI at clinic. 416 HNC eligible patients from at least 10 consultant clusters are required to show a clinically meaningful difference in the primary outcome, that is having less than good overall QOL at the final one-year clinic as measured by the relevant question on the UWQOL-v4 [18].

Before treatment, eligible patients will be asked to consent to participation in the ‘research cohort’. Patients agree to their clinical data being used (Table 1) and to completing research questionnaires before each post-treatment consultation, some of which might be used in their consultation. Completion of all pre-consultation questionnaires including the PCI items will be by computer (desktop, tablet, IPAD). Quality Assurance is by initial training and later booster sessions for consultants and a post consultation survey of those in the PCI arm. Also, in the first six months of the study a random selection of clinic consultations will be taped in order to check how consultants do or do not use the PCI package.

A Steering Group is guiding the research and a joint-site Management group will manage it. Each site will have regular Project Team meetings to review progress. Day to day management issues will be addressed with each unit Lead Researcher. A data manager (based at Aintree R&D) will have overall responsibility for ensuring data quality
and integrity. The study will last three years comprising of set-up and piloting, 12 months of recruitment, 15 months of follow-up and analysis, and then write-up and initial dissemination.

In analysis, the two patient groups will be compared after adjusting for relevant case-mix and for effects of patients being within consultant clusters. A summary flowchart of the key features of this trial is shown as Fig. 1.

### Purpose of the study and hypotheses

The main purpose of this three-year research project is to investigate whether incorporating the PCI into routine head and neck cancer (HNC) follow-up consultations improves the overall QOL of patients. The Null hypothesis is that there is no difference between trial groups in the percentage of patients with less than good overall QOL at one year following the first baseline routine clinic post-treatment.

### Participant eligibility

Eligible patients will have a first occurrence of HNC, and be treated curatively (all sites, stage of disease, treatments). To ensure participation of patients with little or no written or spoken English, translation services will be provided as necessary.

Patients treated with palliative intent and patients with a history of cognitive impairment, psychoses or dementia are excluded, as discussed and identified at the staging/treatment decision-making Multi-Professional Team meeting (MDT). Patients who initially are included and treated curatively but who later start receiving treatment with palliative intent will no longer be asked to continue their participation in the research.

### Method of randomisation

Problems of consultant contamination (from switching back and forth from using to not using the PCI package as would be required with conventional randomisation) indicate this should be a cluster RCT, in that consultants are randomised to ‘using or ‘not using’ the PCI at all their trial clinics. The steering group approved a randomisation process incorporating consultant preference; a method reported previously [19]. The aim is to limit the chance occurrence of PCI-sceptic consultants dominating the PCI group and PCI-enthusiastic consultants the non-PCI group. Those with a strong preference are offered their preferred group and those with no preference are randomised. The allocation process was overseen by the medical statistician involved, before any patient recruitment occurred. At Leeds, three of six consultants preferred to be in the PCI group, while the other three consultants had no preference as to group and were all allocated to the non-PCI control group. At Liverpool, three of eight consultants preferred to be in the non-PCI control group. One of the other five consultants was randomly allocated to the non-PCI control group, leaving four to be in the PCI group. Thus, at the two sites, seven consultants were in each arm of the trial.

### Study intervention

Patient completion of the PCI and its inclusion into the regular review clinic consultation within a summary paper output is the ‘intervention’ and is compared to standard out-patient follow-up. The pre-consultation questionnaires and PCI will be used from the first post-treatment clinic (baseline) onwards for one year. The trial will only apply for routine out-patient follow-ups. Completion of all pre-consultation questionnaires and the PCI is by computer (desktop, tablet, IPAD). Assistance (from trained volunteers) will be available to patients as required. Patients of intervention consultants complete the PCI throughout the trial while patients of control consultants do not complete the PCI at all. All study patients will see their consultant surgeon at 6–8 weekly intervals for planned out-patient review. This might be as joint consultation with the oncologist depending on the configuration of the clinic.

---

**Table 1 Schedule for collecting clinical and demographic details**

| Timepoint                  | Trial Period |
|----------------------------|--------------|
| Enrolment                  | Baseline clinic | Follow-up clinics |
| Gender                     | X            |                |
| DOB                        | X            |                |
| IMD 2015                   | X            |                |
| Smoking and Drinking Details | X          | X\(^a\)       |
| Living Situation           | X            |                |
| Employment                 | X            |                |
| Income                     | X            |                |
| Primary Diagnosis (ICD code) | X            |                |
| Treatment Plan             | X            |                |
| Ethnicity                  | X            |                |
| TNM Stage                  | X            |                |
| Cancer Staging             | X            |                |
| Histology (SNOMED)         | X            |                |
| HPV Status                 | X            |                |
| Co-Morbidity               | X            |                |
| ACE 27                     | X            |                |

\(^a\)Completion at patient 6 and 12 month study visit

---

From the study. Although the PCI could benefit these patients the primary endpoint of this study is QOL at one year. For reasons of engagement and ethics, patients with a history of cognitive impairment, psychoses or dementia are excluded, as discussed and identified at the staging/treatment decision-making Multi-Professional Team meeting (MDT). Patients who initially are included and treated curatively but who later start receiving treatment with palliative intent will no longer be asked to continue their participation in the research.
While waiting for each consultation the Intervention group patients complete the following:

- Health related QOL (UW-QOLv4)
- EQ-5D-5 L
- Distress Thermometer (DT)
- PCI

Intervention patients then take a summary paper output of their data into the consultation (Fig. 2). Post-consultation they will be asked to complete:

- Post-Consultation Patient Feedback about the use of the PCI.

The post consultation data collection will involve self-completion in clinic but either research assisted completion or telephone completion is possible if the patient prefers.

Control patients will complete exactly the same information as intervention patients apart from the PCI and the post consultation feedback on the PCI. They do not take any summary output with them into the consultation. The summary output is a product of the raw inputted data from the patient being run through a software programme that indicates (1) all the items selected from the PCI that the patient wants to discuss (2) those domains from the UWQOL...
questionnaire for which the patient responses suggest a significant problem or dysfunction (using software algorithms derived from earlier work with the UWQOL [20], (3) the patient’s overall QOL and (4) the Distress Thermometer score. The presence of this summary output during the consultation is the difference in reality between the intervention and control groups as far as the interaction between consultant and patient is concerned.

Data collection and outcome measures
Unit Clinical Trials Nurses who recruit eligible patients will keep recruitment and clinic attendance logs. The dedicated funded Unit researchers will collect baseline clinical/demographic data either via a baseline clinic questionnaire, with demographic questions chosen as far as possible to match those included in the head and neck 5000 project [21], or by extraction from baseline clinical records. Baseline data will include cancer site, disease severity, HPV status, treatment details, gender, age, deprivation [IMD from post code], smoking, alcohol, and ACE-27 comorbidity. All clinical outcome data will be collected automatically via IPAD at each consultation. A data manager (based at Aintree) will have overall responsibility for ensuring data quality and integrity.

Primary outcome measure
The primary outcome measure is overall QOL, specifically the percentage with less than good overall QOL at the final one-year clinic as measured by the single UWQOLv4 question [18]. The anticipated result in the control group is 30%. The UW-QOLv4 is a commonly used HNC specific HRQOL questionnaire [22, 23] and has been used with HNC patients at the Aintree Regional Head and Neck Unit since 1995. Over 1000 patients have completed over 5000 UW-QOL questionnaires giving the research team considerable experience in analysing and reporting this QOL measure.

Secondary outcome measures
1. Mean social-emotional subscale score of UW-QOL. The Aintree Research team was involved in developing the UW-QOL subscales, and the social-emotional subscale [20] is the mean of 6 domain scores (each 0–100) - anxiety, mood, pain, activity, recreation and shoulder function. The anticipated result in the control group is a mean score of 75.

2. Distress Thermometer (DT) score of 4 or more (range 0 to 10). The anticipated result in the control group is 34%. The Distress Thermometer (DT) is a single item self-report measure and has been used to screen for distress in various cancers [24–27]. A score of four and above denotes significant distress as this correlates with optimal sensitivity and specificity to the Hospital Anxiety Depression Scale [25, 28].

Cost-effectiveness
1. Quality-adjusted life year (QALY). Quality-adjusted life year (QALY) is used as a summary measure of health benefit for economic evaluation, using the EQ-5D-5 L health index to adjust for patient QOL [29, 30]. QALY is used as a common unit to allow comparisons across different interventions or disease areas [31]. EQ-5D-5 L is a validated generic, health-related, preference-based measure comprising mobility, self-care, usual activities, pain and discomfort, anxiety and depression. These are complemented by a visual analogue scale (VAS) [32], on which patients are asked to indicate their current health from 0 (worst imaginable health) to 100 (best imaginable health) [33].

2. Health service use and costs
Health service use by participating patients will be collected using a Client Service Receipt Inventory (CSRI). CSRI is a form that is usually administered in an interview setting or by self-completion via postal surveys or at clinics – asking them to recall retrospectively the type and frequency of their contacts with primary and secondary care NHS services. A CSRI form adapted to the study was developed using existing CSRIs, available from the DIRUM open access database http://www.dirum.org, as a reference and guidance with input from study researchers. For this trial, services such as physiotherapist, occupational therapist, social worker and others are included. To translate the service use into costs, unit costs from published sources will be applied to the patients’ self-reported service use data and the mean total cost of care per patient over 12 months will be calculated in each group. CSRI is the most common means of collecting service use data, usually with a short recall period of up to 6 months [34, 35], in health economics studies that require data across a range of health care settings. CSRIs were developed first in the field of mental health economics [36], and a review of their use is published by Ridyard and Hughes [37].

6. Cost of the PCI intervention
Resources and materials use for the delivery of the PCI intervention will be recorded and costed and the total cost of the PCI intervention will be calculated.

Sample size calculation
We have used nearly 20 years of accumulated experience with the UW-QOL to estimate a sample size that is
pragmatic enough for a trial to be doable, yet able to detect meaningful differences if they exist. In regard to all UWQOL records collected the percentages of patients reporting less than good overall quality of life were relatively similar over different time periods from diagnosis and the expectation for the trial control group was taken as 30% after about 12 months. Cluster randomized trials require larger sample sizes than the individually randomised design because observations on individuals in the same cluster tend to be correlated, thereby reducing the effective
sample size. The degree of correlation within consultant clusters, as estimated by the intra-class correlation (ICC) was estimated as barely above zero (6.7e-05) for consultants at Aintree. Assuming a likely control group outcome of 30%, an ICC value of 0.01 for the trial and not wishing to miss a halving in outcome rate, then a total of 312 patients from at least 10 consultants were required. After factoring a likely loss of 15% through patient mortality during the follow-up period and a possible maximum loss of 10% from initial non-consent, this then implied a total of 416 eligible patients needing to be approached for participation to the research. This number would also detect a moderate-sized clinical difference of 10 units (75 Vs. 85) in the mean composite social-emotional subscale score, for which an ICC estimate of 0.025 was obtained for consultants within Aintree. Data from an MD project with 325 HNC patients at Aintree gave an estimated 34% with a Distress Thermometer score \( \geq 4 \), and the trial numbers would be sufficient to detect a halving in this outcome.

Statistical analysis
As inference will target the individual patient level, analyses will need to adjust for potential clustering in the data. We will report results for each group (PCI, non-PCI) and the estimated effect size from the use of PCI and its precision (95% confidence interval). For the primary outcome, we will report the intra-cluster correlation coefficient to assess the amount of clustering. In reporting results, we will follow the CONSORT statement extension applicable to cluster RCTs. We will use random effects (multi-level) logistic regression methods and will estimate the effect of PCI after making adjustment for relevant case-mix and for clustering effects of patients being within consultant clusters. Only baseline patient factors will be considered as case-mix adjusters and these include age, gender, treatment, overall clinical stage, tumour site and baseline clinic assessment of whether overall UWQOL was less than good \( (Y/N) \). A \( P \) value \( \leq 0.05 \) is considered statistically significant. Secondary clinical outcomes will be analysed as per protocol.

We will fully cost the delivery of the PCI intervention and associated costs such as training and other materials used. We will use published national average NHS reference consultant costs, accounting for overheads. From an NHS perspective, we will undertake a primary cost-effectiveness analysis of the PCI approach, using the change in % of patients with ‘less than good’ overall QOL between baseline and one-year as the outcome effect, and a subsequent cost-utility analysis using QALY as the outcome effect measured using the EQ-5D-5 L questionnaire. Costs of service use and QALY data will be derived from the CSRI and EQ-5D-5 L questionnaires collected at baseline, 3, 6, 9 and 12 months. The area under the curve method will be used to calculate QALYs, weighting survival by QOL weights obtained from the EQ-5D-5 L. We will compare our findings with unofficial NICE thresholds (ceilings) of £20,000 to £30,000 per QALY. Discounting is unnecessary given the time period. We will account for patient clustering, producing cost-effectiveness planes and acceptability curves (CEACs) to convey to policy makers the probability that PCI approach is cost-effective at different payer thresholds. We will undertake 5000 bootstrapped replications to generate confidence intervals around point estimates. The CSRI also allows us to account for the impact on healthcare service use from intervention participation, important when further rolling out the PCI approach.

Quality assurance (QA)
Quality Assurance will be ensured by initial training and booster sessions for consultants, together with post consultation patient feedback and audio taping of a number of consultations.

Training
There will be a short training programme for staff using the PCI before any patient recruitment. A brief manual/instruction booklet is used to talk through how the PCI should be used in consultations. There will also be two refresher sessions at 4 and 8 months into the trial recruitment phase.

Patients completing the PCI will be asked to complete a post-consultation feedback on paper identified by unique study number and date of clinic; they will be asked to leave this in clinic with the research team; telephone completion of this will also be available. The question is: Did the doctor make reference to the PCI prompt list during the consultation? Response options are ‘Not at all,’ ‘A little,’ ‘Somewhat,’ ‘A great deal’.

Any ‘Not at all’ response will be followed through with the relevant consultant with a view to resolving the issue for future clinics conducted.

Fidelity
In the first months of the study a random selection of clinic consultations will be taped. The additional burden of taping is an argument for focusing on the set-up period in order to check how consultants do or do not use the PCI. The tapes will allow a check on if and how the PCI print out is being used and it will allow for a check for contamination in the non-PCI group. It would be expected that between 3 and 6 months into the study, two clinics from each consultant would be taped.

Management and governance
The trial will be guided by the Steering Group, meeting during the set-up and six-monthly thereafter to ensure progress towards reaching the study’s purpose and to give oversight regarding research governance. Its’ membership
includes an independent chairman, at least two other independent members, the two Unit Lead Investigators, Trial Coordinator (Full Time), Research Practitioner (Part-Time), Medical Statistician, Health Economist, IT/data management representation and a patient representative from each Unit.

There will be joint-Unit management group meetings every three months, membership comprising the two Unit Lead Investigators, dedicated funded researchers, IT/data management representation and a patient representative from each Unit. Statistical and Economic representation as required. Within Unit, there will be monthly Project Team meetings, membership comprising Unit Lead investigator, dedicated funded researchers, Clinical Trials Nurse(s), and patient representative. Day to day management issues will be addressed by Unit Researchers and escalate to the Unit Lead Investigator.

Discussion
There is growing evidence that enhanced symptom monitoring during routine cancer care using patient-reported outcomes benefits patients in respect to HRQOL and survival [38]. The premise of this trial is that the PCI can be integrated into routine clinical consultations with minimal cost implication as the doctor-patient interaction will be more time efficient and facilitate appropriate and targeted multi-professional referrals. The item prompt list approach of the PCI should have direct benefit for the participants. A key issue limiting successful implementation of patient reported outcomes in clinical practice is clinicians’ lack of knowledge on how to effectively utilise PROs data in their clinical encounters [39]. Hence, for this trial there is an educational component and training around the use of the PCI. Also, the patient feedback and analysis of taped consultations will help underpin the evidence related to use of the PCI in the consultation. From this material, it would be possible in the future to develop a more robust training package, informed from the lessons learnt from this trial. In addition, the need for clear system guidelines built into how to most effectively use the PCI for the clinician, the patient and other members of the multi-professional team is recognised [40]. The findings from this trial will inform the development of a PCI manual both for patients and professionals.

The collection of the data in both arms of the trial by touch screen computer-assisted technology (IPAD) has distinct advantages in terms of data capture. With advances in digital health it could be expected that this approach would become regularly employed. Touch screen health-related QOL data collection can be used for scientific documentation as well as in clinical settings [41]. For the purpose of the trial the computer system has been transferred from Aintree to the other sites. This has not been as straightforward as expected. This has caused delays in the use of the IPADs in the other clinics. After completion of this trial, in order to support wider adoption of the PCI approach to patient care, progress is being made in respect to a cloud based platform which should be more readily accessible and easier to use than the current system.

The use of the PCI is a form of intervention in clinic by the consultant. There are other intervention trials that focus to improve function and wellbeing in patients with head and neck cancer. Hansson and colleagues [42] compare a person-centred care intervention in terms of health-related quality of life, disease-specific symptoms or problems, with traditional care as a control group for patients with head and neck cancer. Another trial by van der Hout and co-workers [43] is testing the efficacy, cost-utility and reach of an eHealth self-management application ‘Onkompas’ to obtain optimal supportive care. Both trials explore different tools in a different context to the PCI in this trial. There are many different ways to help enable patients to recover from head and neck cancer, and the possibility of having several evidence based interventions can only help to improve patient’s outcomes and allow centres to select the most appropriate intervention with their healthcare environment. This study has QOL as the primary outcome. This reflects the importance QOL has in terms of outcome following HNC. Also, given the inherent difficulties in QOL evaluation, such as adaptation, response shift, limitations in questionnaire wording, scaling and scoring, it demonstrates the potential power of the PCI to impact positively in patient care. A positive finding from this research will not only serve to promote wider use of the PCI in HNC, but also accelerate the development, piloting and introduction of the PCI in other cancers and chronic conditions. Level 1 evidence as to the benefits of the PCI in HNC care will help drive up standards of care. This research will add substantially to the evidence supporting the use of question prompt lists in NHS practice.

Abbreviations
ACE-27: Adult Co-Morbidity Evaluation 27; AUH: Aintree University Hospital; BAHNON: British Association of Head and Neck Oncology Nurses; CEAC: cost-effectiveness planes and acceptability curves; CHEME: Centre for Health Economics and Medicines Evaluation; CoHaBS: College of Health and Behavioural Sciences; CONSORT: Consolidated standards of Reporting trials; CSRI: Client Service Receipt Inventory (CSRI); DRUM: Database of Instruments for Resource Use Measurement; DT: Distress Thermometer; EHU: Edge Hill University; EPRC: Evidence based Practice Research Centre; EQ-5D-5 L: EuroQol 5 dimension questionnaire; HNC: Head and Neck Cancer; HPV: Herpes Papilloma Virus; HRQOL: Health Related Quality of Life; ICC: Intra-Class Correlation; IMD: Index of Multiple Deprivation; MDT: Multi-Professional Team; NICE: National Institute for Health and Care Excellence; PCI: Patients Concerns Inventory; PCI-HN: Patient Concerns Inventory-Head Neck; PROs: Patient Reported Outcomes; QA: Quality Assurance; QALY: Quality-Adjusted Life Year; QOL: Quality of Life; QPL: Questionnaire prompt lists; R&D: Research and Development; RCT: Randomised Controlled Trial; UWQOL: University of Washington QOL questionnaire; UWQOLv4: University of Washington QOL questionnaire version 4; VAS: Visual Analogue Scale
Acknowledgements
The authors recognise the collaboration between the Research and Development Department at AUH and Edge Hill University with respect the intellectual property related to the PCI. The authors would like to thank Christopher Hughes, Head of Research Support for his help in submitting the grant application.
This paper presents independent research funded by the National Institute for Health Research (NIHR) under its Research for Patient Benefit (RPB) Programme (Grant Reference Number PB-PG-0215-36047). The views expressed are those of the authors and not necessarily those of the NIHS, the NIHR or the Department of Health.

Funding
This trial is funded by the RPB on behalf of the NIHR (PB-PG-0215-36047).

Authors’ contributions
SNR, DL, STY, CA, DM, GMH, RF, CS, AK are responsible for the research question, design of the trial and contributed to the writing of the study protocol. DL is the trial statistician. SNR is the Principle Investigator and corresponding author. CL is the trial manager. CA, DM and RF are patient representatives. All authors sit on the trials Steering group. SNR is responsible for the manuscript. All authors have read and approved the final manuscript.

Ethics approval and consent to participate
The PCI trial has ethical approval from North West - Liverpool Central Research Ethics Committee REC reference: IRAS 16/NW/0465, Project ID: 189554. It also has approval from the Health Research Authority (HRA). The Research and Development Department at Aintree University Hospital NHS Trust (AUH) is coordinating the trial and AUH is the sponsor for the trial.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Regional Maxillofacial Unit, University Hospital Aintree, Liverpool, UK. 2Edge Hill University, Liverpool and Evidence-Based Practice Research Centre (EPIC), Faculty of Health and Social Care, Road, L39 4QP. Ormiskirk, St Helens, UK. 3Head and Neck Clinical Trials, University Hospital Aintree, Clinical Sciences Building, Liverpool, UK. 4Centre for Health Economics and Medicines Evaluation (CHEIME), School of Healthcare Sciences, College of Health and Behavioural Sciences (CoHAlBS), Bangor University, Arduwyd Building, Normal Site, Bangor, UK. 5Leeds Teaching Hospitals and St James Institute of Oncology, Leeds Dental Institute and Leeds General Infirmary, Leeds, UK. 6School of Medicine, Medical & Biological Sciences, North Haugh, St Andrews, UK. 7Southway, Guildford, Surrey, UK. 8Macmillian Health and Wellbeing Service, Ulster Hospital, Upper Newtownards Road, Dundonald, Belfast, UK. 9Oral and Maxillofacial Surgery Department, University, Bristol, Lower Maudlin Street, Bristol, UK. 10Consultant Regional Maxillofacial Unit, University Hospital Aintree, L9 1AE, Liverpool, UK.

Received: 12 August 2017 Accepted: 9 April 2018
Published online: 18 April 2018

References
1. Rogers SN, Clifford N, Lowe D. Patient and carer unmet needs: a survey of the British Association of Head and Neck Oncology Nurses. Br J Oral Maxillofac Surg. 2011;49(3):343–8.
2. Yeh JC, Cheng MJ, Chung CH, Smith TJ. Using a question prompt list as a communication aid in advanced cancer care. J Oncol Pract. 2014;10(3):e137–41.
3. Brown RF, Bylund CL, Li Y, Edsgerdon S, Butow P. Testing the utility of a cancer clinical trial specific question prompt list (QPL-CT) during oncology consultations. Patient Educ Couns. 2012;88(2):311–7.
4. Dilmoska A, Butow PN, Lynch J, Hovey E, Agar M, Beale P, Tattersall MH. Implementing patient question-prompt lists into routine cancer care. Patient Educ Couns. 2012;86(2):252–8.
5. Brown RF, Butow PN, Dunn SM, Tattersall MH. Promoting patient participation and shortening cancer consultations: a randomised trial. Br J Cancer. 2001;85(9):1273–9.
6. Rogers SN, El-Shikhia J, Lowe D. The development of a patients concerns inventory (PCI) to help reveal patients concerns in the head and neck clinic. Oral Oncol. 2009;45(7):555–61.
7. Miller N, Rogers SNA. Review of question prompt lists used in the oncology setting with comparison to the patient concerns inventory. Eur J Cancer Care (Engl). 2016 Mar 14; https://doi.org/10.1111/ecc.12489. [Epub ahead of print].
8. Transforming Patients Experience. https://www.kingfund.org.uk/events/transforming-patient-experience-2015
9. Ideas into action: person-centre care in Practice. The Health Foundation 2014 https://www.health.org.uk/publication/ideas-action-person-centred-practice.
10. Wells M, Semple CJ, Lane C. A national survey of healthcare professionals’ views on models of follow-up; holistic needs assessment and survivorship care for patients with head and neck cancer. Eur J Cancer Care (Engl). 2015; 24(6):873–83.
11. Rogers SN, Lowe D. An evaluation of the head and neck Cancer patient concerns inventory across the Merseyside and Cheshire network. Br J Oral Maxillofac Surg. 2014 Sep;52(7):15–33.
12. Ghazali N, Roe B, Lowe D, Rogers SN. Patients concerns inventory highlights perceived needs and concerns in head and neck cancer survivors and its impact on health-related quality of life. Br J Oral Maxillofac Surg. 2015;53(4):371–9.
13. Girgis A, Cockburn J, Butow P, Bowman D, Schofield P, Stojanovski E, D’Estee C, Tattersall MH, Doran C, Turner J. Improving patient emotional functioning and psychological morbidity; evaluation of a consultation skills training program for oncologists. Patient Educ Couns. 2009;75(5):556–62.
14. Zhou Y, Humphris G, Ghazali N, Fridersich S, Gosselt D, Rogers SN. How head and neck consultants manage patients’ emotional distress during cancer follow-up consultations: a multilevel study. Eur Arch Otorhinolaryngol. 2015;272(9):2473–81.
15. Ghazali N, Cadwallader E, Lowe D, Humphris G, Ozakinci G, Rogers SN. Fear of recurrence among head and neck cancer survivors: longitudinal trends. Psychooncology. 2015;24(8):807–13.
16. Kanatas A, Humphris G, Lowe D, Rogers SN. Further analysis of the emotional consequences of head and neck cancer as reflected by the Patients’ concerns inventory. Br J Oral Maxillofac Surg. 2015;53(8):711–8.
17. Ghazali N, Roe B, Lowe D, Tandon S, Jones T, Brown J, Shaw R, Rik J, Rogers SN. Screening for distress using the distress thermometer and the University of Washington Quality of Life in post-treatment head and neck cancer survivors. Eur Arch Otorhinolaryngol. 2017;274(3):2253–60.
18. Rogers SN, Gwane S, Lowe D, Humphris G, Yueh B, Weymuller EA. The addition of mood and anxiety domains to the University of Washington Quality of life scale. Head Neck. 2002;24(6):521–9.
19. Verhaeghe N, Clays E, Vereeken C, De Maereene J, Maes L, Van Heeringen C, De Bacquier D, Annemans L. Health promotion in individuals with mental disorders: a cluster preferred randomized controlled trial. Br J Psychiatry. 2013;203:657. https://doi.org/10.1192/ebhj.2009.193.09.03.
20. Rogers SN, Lowe D, Yueh B, Weymuller EA. The physical function and social-emotional function subscales of the University of Washington Quality of Life questionnaire (UW-QOL). Arch Otolaryngol Head Neck Surg. 2010;136(4):352–7.
21. Ness AR, Waylen A, Hurley K, Jeffreys M, Penfold C, Pring M, Leasy S, Allmark C, Toms R, Ring S, Peters TJ, Hollingsworth W, Worthington H, Nutting C, Fisher S, Rogers SN, Thomas SJ. Head and neck 5000 study team. Establishing a large prospective clinical cohort in people with head and neck cancer as a biomedical resource: head and neck 5000. BMC Cancer. 2014;14:973. https://doi.org/10.1186/1471-2407-14-973.
22. Kanatas AN, Mehnna H, Lowe D, Rogers SN. A second national survey of health-related quality of life questionnaires in head and neck oncology patients. Head Neck. 2013;35(6):742–9.
23. Verhaeghe N, Clays E, Vereeken C, De Maereene J, Maes L, Van Heeringen C, De Bacquier D, Annemans L. Health promotion in individuals with mental disorders: a cluster preferred randomized controlled trial. Br J Psychiatry. 2013;203:657. https://doi.org/10.1192/ebhj.2009.193.09.03.
24. Fishlock S, Rogers SN, Thomas SJ. Head and neck 5000 study team. Establishing a large prospective clinical cohort in people with head and neck cancer as a biomedical resource: head and neck 5000. BMC Cancer. 2014;14:973. https://doi.org/10.1186/1471-2407-14-973.
25. Fox S, Rogers SN, Thomas SJ. Head and neck 5000 study team. Establishing a large prospective clinical cohort in people with head and neck cancer as a biomedical resource: head and neck 5000. BMC Cancer. 2014;14:973. https://doi.org/10.1186/1471-2407-14-973.
27. Hegel MT, Collins ED, Kearing S, Gillock KL, Moore CP, Ahles TA. Sensitivity and specificity of the distress thermometer for depression in newly diagnosed breast cancer patients. Psychooncology. 2008 Jun;17(6):556–60.

28. Shim EJ, Shin YW, Jeon HJ, Hahn BJ. Distress and its correlates in Korean cancer patients: pilot use of the distress thermometer and the problem list. Psychooncology. 2008 Jun;17(6):549–55.

29. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.

30. Morris S, Devlin N, Parkin D. Economic analysis in health care. Chichester: John Wiley & Sons Ltd, 2007.

31. National Institute for Health and Clinical Excellence. (NICE). Process and methods guides: guide to the methods of technology Appraisal. 2013; https://www.nice.org.uk/process/pmg9/chapter/foreword.

32. Dolan P, Gudex C, Kind P, Williams A. A social tariff for EuroQol: Results from a UK general population survey, Discussion paper No. 138. York: Centre for Health Economics, University of York; 1995.

33. EuroQOL. EQ-5D User Guide version. 2015:50. https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/.

34. Jobe JB, White AA, Kelley CL, Mingay DJ, Sanchez MJ, Loftus EF. Recall strategies and memory for health care visits. Milbank Mem Fund Q. 1990; 68(2):171–89.

35. Chisholm D, Knapp MRU, Knudsen HC, Amaddeo F, Gale L, Van Wijngaarden B. Client socio-demographic and service receipt inventory - European version: development of an instrument for international research: EPSILON study. European Psychiatric Services: Inputs Linked to Outcome Domains and Needs Br J Psychiatry Suppl. 2000;39s:28–33.

36. Knapp M, Beecham J. Costing mental health services. Psychol Med. 1990; 20(4):893–908. Review

37. Ridyard CH, Hughes DA. Methods for the collection of resource use data within clinical trials: a systematic review of trials funded by the UK health technology assessment programme. Value Health. 2010;13(8):S67–72.

38. Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, Rogak L, Bennett AV, Dueck AC, Atkinson TM, Chou JF, Dulko D, Sit L, Barz A, Novotny P, Fruicone M, Sloan JA, Schrag D. Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol. 2016;34(6):557–65.

39. Santana MJ, Haverman L, Absalom K, Takeuchi E, Feeny D, Grootenhuis M, Velikova G. Training clinicians in how to use patient-reported outcome measures in routine clinical practice. Qual Life Res. 2015;24(7):1707–18.

40. Kotronoulas G, Kearney N, Maguire R, Harwood A, Di Domenico D, Croy S, MacCallum S. What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials. J Clin Oncol. 2014;32(14):1480–501.

41. de Bree R, Verdonck-de Leeuw IM, Keizer AL, Houfkeela A, Leemans CR. Touch screen computer-assisted health-related quality of life and distress data collection in head and neck cancer patients. Clin Otolaryngol. 2008; 33(2):138–42.

42. Hansson E, Carlstrom E, Olsson LE, Nyman J, Koinberg I. Can a person-centred-care intervention improve health-related quality of life in patients with head and neck cancer? A randomized, controlled study. BMC Nurs. 2017;16:9. https://doi.org/10.1186/s12912-017-0206-6. eCollection 2017.

43. van der Hout A, van Uden-Kraan CF, Witte BI, VMH C, Jansen F, Leemans CR, Cuypers P, de Poll-Franse LV, Verdonck-de Leeuw IM. Efficacy, cost-utility and reach of an eHealth self-management application ‘Oncokompas’ that helps cancer survivors to obtain optimal supportive care: study protocol for a randomised controlled trial. Trials. 2017;18(1):228. https://doi.org/10.1186/s12967-017-1952-1.